Wellbutrin Users Seek To Revive Class Cert. Bid

Law360, New York (October 19, 2010, 3:05 PM EDT) -- Wellbutrin SR users who say GlaxoSmithKline PLC used sham patent litigation to avoid competition have asked a federal court to clarify whether they can refile a previously denied motion for class certification, saying they have a plan to address prior shortcomings.

The putative class, comprised of indirect purchasers of GSK's popular antidepressant, proposed a schedule Monday in the U.S. District Court for the Eastern District of Pennsylvania that would allow it to file an amended motion for class cert by Dec. 15, with GSK's opposition brief...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.